ClinicalTrials.gg
TerminatedNCT02737306GVHDUpdated Mar 12, 2024Results posted

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

A Phase 2 interventional study of PRO 140 and Placebo in Graft Vs Host Disease, sponsored by CytoDyn, Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Study terminated due to lack of enrolment..

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
284th of 389
11 · median 30
Started
2017
with 16 others
Phase 2
164 of 454
15 open now
Registered
310th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 284th largest by enrollment of the 389 interventional ones that give a count, is one of 17 that started in 2017, is one of 164 in phase 2, and was the 310th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Allogeneic Stem-Cell Transplantation.

Read the detailed description

This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the feasibility of the use of PRO 140 as an add-on therapy to standard GVHD prophylaxis treatment for prevention of acute GVHD in adult patients with AML or MDS undergoing allogeneic HCT.

In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e., 30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the day of stem cell infusion (Day 0), and then weekly for 30 days (at Week 1, Week 2, Week 3 and Week 4) after which it will be administered every two weeks for up to 100±7 days (at Week 6, Week 8, Week 10, Week 12 and Week 14). Subjects will return to clinic for two Follow-up visits at 2 weeks after the last treatment visit, and one year after the first treatment visit.

03

Conditions studied

  • Graft Vs Host Disease

Browse trials for

Keywords

  • Allogeneic
  • Stem Cell
  • Transplantation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria to be included in the study:

  1. Patients diagnosed with AML or MDS per below:

    • Patients with a history of or pathologically confirmed diagnosis of AML and \< 5% blasts in the peripheral blood or bone marrow (per bone marrow aspiration and/or within 6 weeks prior to screening) scheduled to undergo stem-cell transplantation
    • Patients with a histologically or pathologically confirmed diagnosis of MDS with \< 10% blasts in the bone marrow (per bone marrow aspiration and/or biopsy within 6 weeks prior to screening) scheduled to undergo allogeneic stem-cell transplantation
  2. (ECOG) performance status score ≤ 2
  3. Patients must have normal organ function as defined below:

    Myeloablative allogeneic HCT:

    • Males and females, age ≥18 and ≤ 65 years of age
    • Total ≤ 2 mg/dL (except in patients with Gilbert's Syndrome)
    • /ALT ≤ 3 times institutional (except in patients with leukemic infiltration of liver)
    • Serum creatinine ≤ 2 mg/dL and ≥ 60 ml/hr
    • Diffusing capacity of the lung for carbon monoxide (DLCO) > 50% predicted with no symptomatic pulmonary disease
    • Cardiac ≥ 50%. If between 40-49% a cardiology consult is required
    • Clinically normal resting 12-lead at screening visit or, if abnormal, considered not by the PI
  4. Patients must have a reasonable expectation of ≥ 6 months survival
  5. The donor-recipient HLA match criteria required for participation in this protocol are not research subjects in this study and they must meet criteria as National Marrow Donor Program (NMDP) donors. Procedures for selection of donors and stem cell dose will follow FDA requirements for Blood Products (21 CFR 640) and Human Cellular and Tissue Based Products (21 CFR 1271). The standard institutional practices for stem cell transplants also will be followed. The donors are:

    • HLA-Identical Sibling (6/6): Minimal typing necessary is serologic typing for class I (AB) and molecular typing for class II (DRB1)
    • Matched Unrelated Donor (8/8): Molecular identity at HLA A, B, C and DRB1 by high-resolution typing
    • Matched Related and Unrelated Donor (7/8): high-resolution molecular typing at the following loci is required: HLA A, B, C and DRB1
  6. Both male and female patients and their partners of must agree to use appropriate methods (birth control pills, barriers, or abstinence) throughout the study duration (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
  7. Patients must understand and voluntarily sign an form

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from the study:

  1. Patients not expected to be available for follow-up for at least 114 days after transplant
  2. Patients who have received prior stem cell-transplantation
  3. Patients who receive post-transplant high dose cyclophosphamide
  4. Patients with active central nervous system (CNS) involvement by malignant cells
  5. Patients receiving other drugs for . Co-enrollment in other clinical trials that do not include experimental GVHD therapies is allowed.
  6. Prior use of any experimental or approved CCR5 modulator including maraviroc and PRO 140
  7. Patients with uncontrolled bacterial, viral or fungal infections including diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A or a new diagnosis of or C within 24 weeks of dosing)
  8. Currently active second other than non-melanoma skin cancers
  9. Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use
  10. Patients who are positive
  11. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
  12. Subjects on chronic therapy > 5 mg/day within 2 weeks of screening except for inhaled, nasal, or topical steroids
  13. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e. 30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection. Placebo will be administered -2/-3 days before the stem cell infusion, on the day of stem cell infusion (Day 0) and thereafter on days 7, 14, 21, 28, 42, 56, 70, 84 and 98 as per the study schedule of assessments. Each vial of the Placebo contains 5mM Histidine, 15 mM Glycine, 95 mM Sodium Chloride, 0.3% (w/v) Sorbitol, 0.005% (w/v) Polysorbate 20 at a pH of 5.5. Each 350 mg dose of placebo consist of 2 SC injections of placebo (5mM Histidine, 15 mM Glycine, 95 mM Sodium Chloride, 0.3% (w/v) Sorbitol, 0.005% (w/v) Polysorbate 20 at a pH of 5.5) of 2 X 1 mL/inj. on opposite sides of abdomen.

    Drug: Placebo

  • Experimental
    350 mg Pro140

    In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e.,30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection. PRO 140 will be administered -2/-3 days before the stem cell infusion, on the day of stem cell infusion (Day 0) and thereafter on days 7, 14, 21, 28, 42, 56, 70, 84 and 98 as per the study schedule of assessments. Each vial of the PRO 140 product contains 1.4 mL antibody at 175 mg/ml in a buffer containing 5 mM L-histidine, 15.0 mM glycine, 95 mM sodium chloride, 0.3% (w/v) sorbitol, 0.005% (w/v) polysorbate 20 (Tween 20®), and sterile water for injection, at pH of 5.5. Each 350 mg dose of PRO 140 will consist of 2 SC injections of PRO 140 (2 X 1 mL/inj.) on opposite sides of abdomen.

    Drug: PRO 140

Interventions

  • PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

    Also known as: Humanized monoclonal antibody to CCR5

  • DrugPlacebo

    Placebo in parenteral solution.

06

What researchers measure

Primary outcomes

  1. Incidence of Acute GVHD by Day 100

    Incidence of Grade II, Grade III or Grade IV acute GVHD by Day-100

    Time frame: 100 days from first treatment (100 Days post treatment)

Secondary outcomes

  1. Incidence of Severe and Life-threatening (Grade III and Grade IV) Acute GVHD by Day-100

    The number and percentages of subjects with severe and life-threatening (Grade III and Grade IV) acute GVHD by Day-100 will be presented. Chi-square/ Fisher's exact test will be used to compare the incidence between the treatment groups.

    Time frame: 100 Days post-treatment

  2. Incidence of Organ-specific Acute GVHD by Day-100

    The number and percentages of subjects with organ-specific acute GVHD by Day-100 will be presented by organ category. Chi-square/ Fisher's exact test will be used to compare the incidence between the treatment groups.

    Time frame: 100 Days post-treatment

  3. Donor Engraftment Evaluated by T-cell and Myeloid Chimerism in Peripheral Blood

    The number and percentages of subjects with donor engraftment failure evaluated by T-cell and myeloid chimerism in peripheral blood will be presented by different treatment groups. Chi-square/ Fisher's exact test will be used to compare the incidence of donor engraftment failure.

    Time frame: 365 days post-initial treatment (T1 Visit) (+/- 14 days)

  4. Neutrophil and Platelet Count Recovery

    The number and percentages of subjects with neutrophil and platelet count recovery will be presented. Chi-square/ Fisher's exact test will be used to compare the incidence of neutrophil recovery and of platelet recovery between treatment groups.

    Time frame: 100 Days post treatment

  5. Changes in ECOG Performance Score

    The raw and change from baseline in ECOG performance score will be summarized for each assessment scheduled visit (i.e., Screening visit, Treatment Visits 1, 4, 7, 9, 11, Follow-up Visit 1and Unscheduled Visit(s)). Descriptive statistics (n, mean, standard deviation, median, minimum and maximum) will be presented by treatment group. If the Normality assumption is met, t-test will be used to compare the mean of ECOG performance score between the treatment groups and if the Normality assumption is not met, a non-parametric method will be used.

    Time frame: 100 Days post treatment visit 1

  6. GVHD-free Survival (GFS)

    GFS will be defined as the elapsed time between the date of transplant until GVHD related death. GVHD-free survival will be compared between the treatment groups using Log-rank test and Kaplan-Meier methods will be used to depict the survival curves.

    Time frame: 100 Days post treatment visit T1

  7. Tolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants (Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions

    All data from tolerability assessments of repeated subcutaneous administration of PRO 140 as assessed by study participants and by investigator-evaluation of injection site reactions will be summarized using n, mean, Standard Deviation (SD), minimum and maximum values.

    Time frame: 365 days post-treatment (+/- 14 days)

  8. Frequency of Treatment Emergent Adverse Events and Serious Adverse Events

    Frequency of treatment emergent adverse events and treatment emergent serious adverse events.

    Time frame: 100 Days post treatment

  9. AML or MDS Relapse Rate by Day-100

    AML or MDS relapse rate by Day-100 will be summarized and present by treatment groups.

    Time frame: 100 Days post treatment

  10. Changes and Shifts in Laboratory Measurements Over Time

    Safety Assessment- The laboratory measurements will include Routine CBC, Biochemistry and Urinalysis. * Routine CBC includes hemoglobin, hematocrit (HCT), red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count (%), absolute neutrophils count (ANC) and platelets count. * Biochemistry profile includes assessment of Hepatic function indicators: total and direct bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, Lactate dehydrogenase (LDH); Renal function indicators: Blood Urea Nitrogen (BUN), creatinine; Electrolytes: sodium, potassium, chloride, calcium and bicarbonate; Other: glucose (random), cholesterol (total) * Urinalysis for color, appearance, specific gravity, pH, protein, glucose, occult blood, ketones, RBC, WBC, epithelial cells, bacteria, casts, crystals

    Time frame: 365 days post-treatment (+/- 14 days)

  11. Changes in Electrocardiogram (ECG) Parameters Over Time

    Safety Assessment-The following ECG parameters will be evaluated: ventricular rate (beats per minute), PR interval (msec), QRS interval (msec), QT interval (msec), and QTc interval (msec).

    Time frame: 365 days post-treatment (+/- 14 days)

07

Results

Posted Mar 12, 2024
Limitations and caveats
This study was stopped prior to completion due to lack of enrolment.

Participant flow

Participant flow — Overall Study
MilestonePRO 140Placebo
Started65
Completed25
Not completed40
Withdrew: Adverse event30
Withdrew: Enrolment and treatment halted by sponsor.10

Outcome measures

PrimaryIncidence of Acute GVHD by Day 100

Incidence of Grade II, Grade III or Grade IV acute GVHD by Day-100

Time frame:
100 days from first treatment (100 Days post treatment)

No measurements were reported for this outcome.

SecondaryIncidence of Severe and Life-threatening (Grade III and Grade IV) Acute GVHD by Day-100

The number and percentages of subjects with severe and life-threatening (Grade III and Grade IV) acute GVHD by Day-100 will be presented. Chi-square/ Fisher's exact test will be used to compare the incidence between the treatment groups.

Time frame:
100 Days post-treatment

No measurements were reported for this outcome.

SecondaryIncidence of Organ-specific Acute GVHD by Day-100

The number and percentages of subjects with organ-specific acute GVHD by Day-100 will be presented by organ category. Chi-square/ Fisher's exact test will be used to compare the incidence between the treatment groups.

Time frame:
100 Days post-treatment

No measurements were reported for this outcome.

SecondaryDonor Engraftment Evaluated by T-cell and Myeloid Chimerism in Peripheral Blood

The number and percentages of subjects with donor engraftment failure evaluated by T-cell and myeloid chimerism in peripheral blood will be presented by different treatment groups. Chi-square/ Fisher's exact test will be used to compare the incidence of donor engraftment failure.

Time frame:
365 days post-initial treatment (T1 Visit) (+/- 14 days)

No measurements were reported for this outcome.

SecondaryNeutrophil and Platelet Count Recovery

The number and percentages of subjects with neutrophil and platelet count recovery will be presented. Chi-square/ Fisher's exact test will be used to compare the incidence of neutrophil recovery and of platelet recovery between treatment groups.

Time frame:
100 Days post treatment

No measurements were reported for this outcome.

SecondaryChanges in ECOG Performance Score

The raw and change from baseline in ECOG performance score will be summarized for each assessment scheduled visit (i.e., Screening visit, Treatment Visits 1, 4, 7, 9, 11, Follow-up Visit 1and Unscheduled Visit(s)). Descriptive statistics (n, mean, standard deviation, median, minimum and maximum) will be presented by treatment group. If the Normality assumption is met, t-test will be used to compare the mean of ECOG performance score between the treatment groups and if the Normality assumption is not met, a non-parametric method will be used.

Time frame:
100 Days post treatment visit 1

No measurements were reported for this outcome.

SecondaryGVHD-free Survival (GFS)

GFS will be defined as the elapsed time between the date of transplant until GVHD related death. GVHD-free survival will be compared between the treatment groups using Log-rank test and Kaplan-Meier methods will be used to depict the survival curves.

Time frame:
100 Days post treatment visit T1

No measurements were reported for this outcome.

SecondaryTolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants (Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions

All data from tolerability assessments of repeated subcutaneous administration of PRO 140 as assessed by study participants and by investigator-evaluation of injection site reactions will be summarized using n, mean, Standard Deviation (SD), minimum and maximum values.

Time frame:
365 days post-treatment (+/- 14 days)

No measurements were reported for this outcome.

SecondaryFrequency of Treatment Emergent Adverse Events and Serious Adverse Events

Frequency of treatment emergent adverse events and treatment emergent serious adverse events.

Time frame:
100 Days post treatment

No measurements were reported for this outcome.

SecondaryAML or MDS Relapse Rate by Day-100

AML or MDS relapse rate by Day-100 will be summarized and present by treatment groups.

Time frame:
100 Days post treatment

No measurements were reported for this outcome.

SecondaryChanges and Shifts in Laboratory Measurements Over Time

Safety Assessment- The laboratory measurements will include Routine CBC, Biochemistry and Urinalysis. * Routine CBC includes hemoglobin, hematocrit (HCT), red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count (%), absolute neutrophils count (ANC) and platelets count. * Biochemistry profile includes assessment of Hepatic function indicators: total and direct bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, Lactate dehydrogenase (LDH); Renal function indicators: Blood Urea Nitrogen (BUN), creatinine; Electrolytes: sodium, potassium, chloride, calcium and bicarbonate; Other: glucose (random), cholesterol (total) * Urinalysis for color, appearance, specific gravity, pH, protein, glucose, occult blood, ketones, RBC, WBC, epithelial cells, bacteria, casts, crystals

Time frame:
365 days post-treatment (+/- 14 days)

No measurements were reported for this outcome.

SecondaryChanges in Electrocardiogram (ECG) Parameters Over Time

Safety Assessment-The following ECG parameters will be evaluated: ventricular rate (beats per minute), PR interval (msec), QRS interval (msec), QT interval (msec), and QTc interval (msec).

Time frame:
365 days post-treatment (+/- 14 days)

No measurements were reported for this outcome.

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRO 1402/6 (33.3%)6/6 (100%)6/6 (100%)
Placebo0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPRO 140Placebo
PneumoniaInfections and infestations2/60/5
PyrexiaGeneral disorders0/61/5
Acute graft versus host diseaseImmune system disorders1/60/5
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/60/5
AzotaemiaRenal and urinary disorders1/60/5
CholelithiasisHepatobiliary disorders1/60/5
Cytomegalovirus viraemiaInfections and infestations1/60/5
Generalised tonic-clonic seizureNervous system disorders1/60/5
Jugular vein thrombosisVascular disorders1/60/5
MyopathyMusculoskeletal and connective tissue disorders1/60/5
Most frequent other events
Showing 10 of 153
Most frequent other events
EventPRO 140Placebo
Platelet count decreasedInvestigations2/65/5
StomatitisGastrointestinal disorders5/63/5
DiarrhoeaGastrointestinal disorders2/64/5
HypomagnesaemiaMetabolism and nutrition disorders3/64/5
AnaemiaBlood and lymphatic system disorders4/63/5
NauseaGastrointestinal disorders4/62/5
Neutrophil count decreasedInvestigations4/63/5
White blood cell count decreasedInvestigations4/63/5
DizzinessNervous system disorders4/60/5
HeadacheNervous system disorders4/62/5

Baseline characteristics

The Intent-to-Treat (ITT) population is defined as the set of subjects who are randomized to PRO 140 or placebo. The ITT population will be the primary analysis population for the analysis of primary and secondary endpoints

Age, Categorical
Age, Categorical(Participants)PRO 140PlaceboTotal
<=18 years000
Between 18 and 65 years6511
>=65 years000
Age, Continuous
Age, Continuous(years)PRO 140PlaceboTotal
Mean43 (25 to 61)54 (39 to 63)48 (25 to 63)
Sex: Female, Male
Sex: Female, Male(Participants)PRO 140PlaceboTotal
Female426
Male235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PRO 140PlaceboTotal
Hispanic or Latino011
Not Hispanic or Latino6410
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PRO 140PlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5510
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PRO 140PlaceboTotal
United States6511
HIV rapid antigen test
HIV rapid antigen test(Participants)PRO 140PlaceboTotal
HIV rapid antigen test negative6511
HIV rapid antigen test positive000
08

Study locations

8 sites
  • University of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Loyola University Medical Center Cardinal Bernardin Cancer Center
    Maywood, Illinois 60153, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University of Minnesota
    Minneapolis, Minnesota 55409, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Texas Transplant Institute Methodist Hospital
    San Antonio, Texas 78229, United States
  • West Virginia University Medicine
    Morgantown, West Virginia 26506, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Apr 2021, 47 months.

Results were first posted in Mar 2024, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2016
First posted
Apr 13, 2016
StartActual
May 14, 2017
Primary completionActual
Apr 14, 2021
CompletionActual
Sep 30, 2021
Results first posted
Mar 12, 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02737306
Lead sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
May 14, 2017
Primary completion
Apr 14, 2021
Completion
Sep 30, 2021
Results posted
Mar 12, 2024
Last update
Mar 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion